PET/MRI in Rectal Cancer
ConditionRectal Cancer
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAHS Cancer Control Alberta
About this trial
The purpose of this study is to see which participants have a better treatment response using PET/MRI imaging to study the removed tumor, after they have received a total neoadjuvant therapy (TNT). The treatment choice of long course chemo-radiotherapy treatment will be determined by institutional policy.
The researchers will also be looking at whether this study could significantly improve the future management and quality of life of rectal cancer patients.
Eligibility criteria
Qualifiers
Patients with histologically proven adenocarcinoma of the rectum.
Clinical stage 2-3 rectal adenocarcinoma, cT3/4N0/M0 or Tx N1-2/M0, within 16 cm from anal verge (lesion below the sacral promontory).
Patients deemed suitable to undergo TNT followed by surgical resection.
Male or female ≥ 18 years of age.
Disqualifiers
Patient receiving short course radiotherapy alone for rectal cancer.
Patient receiving standard TNT.
Patients with metastatic disease.
Prior pelvic radiotherapy or chemotherapy.
Trial design
Treatments tested in this trial
- Total Neo-adjuvant Therapy
- 18FDG-PET/MRI scan
Treatment groups
40 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov